Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells

• Autor(a) principal: Guimarães, Douglas M.
• Data de Publicação: 2016
• Outros Autores: Almeida, Luciana Oliveira, Martins, Manoela Domingues, Warner, Kristy, Santos-Silva, Alan Roger, Vargas, Pablo Agustin, Nunes, Fábio Daumas, Squarize, Cristiane Helena, Nor, Jacques Eduardo, Castilho, Rogerio Moraes
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/183990
• topic: Patologia bucal; Carcinoma bucal; Células-tronco neoplásicas

Mucoepidermoid carcinoma (MEC) is the most common malignancy of salivary glands. The response of MEC to chemotherapy is unpredictable, and recent advances in cancer biology suggest the involvement of cancer stem cells (CSCs) in tumor progression and chemoresistance and radioresistance phenotype. We found that histone acetyltransferase inhibitors (HDACi) were capable of disrupting CSCs in MEC. Furthermore, administration of HDACi prior to Cisplatin (two-hit approach) disrupts CSCs and sensitizes tumor cells to Cisplatin. Our findings corroborate to emerging evidence that CSCs play a key role in tumor resistance to chemotherapy, and highlights a pharmacological two-hit approach that disrupts tumor resistance to conventional therapy.